TEVA vs VRTX
Teva Pharmaceutical Industries Ltd (TEVA) and Vertex Pharmaceuticals Inc / Ma (VRTX) are both filed with the SEC under Pharmaceutical Preparations. VRTX is 3.2× TEVA's size by market cap ($138.8B against $43.8B); VRTX trades at the higher fiscal-year P/E (35.7× against 31.1×); VRTX reports the higher net margin (32.9% against 8.2%); VRTX grew sales faster over three years (+10.4% against +5.0%); and over the past year TEVA returned +102.0% against VRTX's +38.2%.
| TEVA | VRTX | |
|---|---|---|
| Last close | $36.44 | $541.69 |
| Market cap | $43.8B | $138.8B |
| P/E (FY) | 31.1× | 35.7× |
| P/S | 2.5× | 11.6× |
| EV/EBITDA | 13.3× | — |
| Gross margin | 51.8% | — |
| Operating margin | 12.5% | 34.8% |
| Net margin | 8.2% | 32.9% |
| Return on equity | 21.2% | 22.5% |
| Sales growth (3y) | +5.0% | +10.4% |
| EPS growth (3y) | — | +6.1% |
| 1-year return | +102.0% | +38.2% |
Screener snapshot — prices as of 2026-08-28. Each side's last close is the most recent session the snapshot holds for that company, which can be an earlier one, and its 1-year return is measured to that close. Market caps struck on 2026-08-27. Last close, market cap and the 1-year return are price figures; every other row is computed over the company's latest filed fiscal year — FY2025 (ended 2025-12-31) for both. — not published for this company. A ratio goes unpublished for more than one reason: a component the calculation needs is not on file, the filing does not tag the line it is read from, or the calculation is not defined on the filed basis — EV/EBITDA is not printed on non-positive EBITDA, and return on equity is not computed on a zero or negative equity base.
Who holds them, and who has traded them
| TEVA | VRTX | |
|---|---|---|
| Institutional holders (13F) | 649 | 1,679 |
| Insider buyers − sellers (180d) | -5 | -5 |
| Congressional trades disclosed (180d) | 1 | 1 |
| Executive-branch officials on file — trades disclosed (180d) | 0 | 14 |
Counts only. The congressional figures count transactions dated in the trailing 180 days and disclosed in STOCK Act periodic transaction reports; amounts are filed as ranges and are never summed. The executive-branch figures count the same window of transactions, and they are scoped to one roster. The officials OGE posts for direct download. Insider buyers − sellers counts distinct people filing open-market Form 4 purchases minus distinct people filing open-market sales over the trailing 180 days, capped at ±5.
TEVA vs VRTX: common questions
- Is TEVA bigger than VRTX?
- VRTX carries the larger market cap — $138.8B against $43.8B, both struck on 2026-08-27.
- Which trades at a higher P/E, TEVA or VRTX?
- VRTX, at a fiscal-year 35.7× against 31.1× for TEVA. Both are price ÷ latest full-year diluted earnings per share, not a trailing-twelve-month P/E.
- How have TEVA and VRTX performed over the past year?
- TEVA returned +102.0% and VRTX +38.2%, measured on the trailing calendar year to the last close.
- How many institutions hold TEVA and VRTX?
- 649 13F filers report a position in TEVA and 1,679 in VRTX, on the latest quarter in the panel.
- Are TEVA and VRTX in the same industry?
- Both are filed with the SEC under Pharmaceutical Preparations, which is the classification this pairing is built on.
TEVA overview → · VRTX overview → · TEVA institutional ownership → · VRTX institutional ownership → · Congress and TEVA → · Congress and VRTX → · Executive branch and VRTX →
More in Pharmaceutical Preparations: ABBV vs ABT · ABBV vs ONC · ABBV vs REGN · ABBV vs TEVA
Stock comparisons lists every pair this site publishes.
Source: SPZCO — https://spzco.com/vs/teva-vs-vrtx